Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus

Сlinical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-СoV-2 Infection Prophylactic Treatment in Republic of Belarus

Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection prophylactic treatment.

Study Overview

• Status: Unknown
• Conditions: Covid19
• Intervention / Treatment: Biological: Gam-COVID-Vac; Other: Placebo

Detailed Description

Overall of 110 volunteers aged 18 to 60 should be screened taking into account possible early departure from the study. It is supposed that 100 subjects will complete all screening procedures and will be randomized in a 3:1 ratio into two groups: a control group (using placebo, 25 subjects) and a study group (using Gam-COVID-Vac Combined Vector Vaccine to Prevent Coronavirus Infection Caused by SARS-CoV-2", 75 subjects).

The duration of participation in the study for one subject will be 180±14 days after the first dose of IMP/placebo, during which each subject will undergo a screening visit and five face-to-face visits to the doctor-researcher. Intramuscular injection of IMP or placebo will be carried out on vaccination visits N 1 and N 2 (Day 0 and Day 21±2). Further observation visits No 3, 4, 5 will be conducted on days 28±2, 42±2 and 180±14 respectively. It is allowed to conduct observation visits No. 3, 4 via telephone contact (TC). During the monitoring visits, all subjects of the study will be assessed on key vital indicators and data will be collected on changes in the status and well-being of the subjects since the previous visit.

The duration of participation in the study for one subject will be 180±14 days after the first dose of IMP/placebo, during which each subject will undergo a screening visit and five observation visits. Intramuscular injection of IMP or placebo will be carried out on vaccination visits N 1 and N 2 (Day 0 and Day 21±2). Further observation visits No 3, 4, 5 will be conducted on days 28±2, 42±2 and 180±14 respectively.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belarus
  • Minsk, Belarus
    • Health Institution "14th Central Regional Polyclinic of the Partisan district of Minsk"
  • Minsk, Belarus
    • Health Institution "19th Central Regional Polyclinic of the Pervomaysk district of Minsk"
  • Minsk, Belarus
    • Health Institution "1st Central Regional Clinical Polyclinic of the Central district of Minsk"
  • Minsk, Belarus
    • Health Institution "28th Regional Polyclinic of Minsk"
  • Minsk, Belarus
    • Health Institution "4th City Polyclinic of Minsk"
  • Minsk, Belarus
    • Health Institution "5th City Clinical Polyclinic of Minsk"
  • Minsk, Belarus
    • Health Institution "Minsk Order of the Red Banner of Labor Regional Clinical Hospital
  • Vitebsk, Belarus
    • Health Institution "Vitebsk Regional Clinical Hospital"

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 58 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The subject's written informed consent to participate in the study;
• Male and female subjects between the ages of 18 and 60 years (inclusive).
• A negative test result for HIV, hepatitis, syphilis;
• Negative result of research on antibodies IgM and IgG to SARS Cov2 by enzyme-linked immunosorbent assay;
• A negative result of the COVID-2019 study, as determined by the PCR method at the screening visit;
• Lack of COVID-2019 in anamnesis;
• Lack of contact of the subject with COVID-2019 patients for at least 14 days before inclusion in the study (according to the participant);
• Agreement to use effective contraceptive methods throughout the study period;
• Negative pregnancy test based on the results of a urine test at a screening visit (for women of childbearing age);
• A negative test for the presence of narcotic substances and psycho-stimulating drugs in the urine at the screening visit;
• Negative alcohol test at the screening visit;
• Lack of pre-existing post-vaccination reactions or post-vaccination complications following the use of immunobiological drugs;
• No acute infectious and/or respiratory diseases for at least 14 days before inclusion in the study.

Exclusion Criteria:

• Any vaccination/immunization carried out within 30 days prior to enrollment in the study;
• Treatment with steroids (except hormonal contraceptives) and/or with immunoglobulins or other blood products not completed 30 days before inclusion in the study;
• Immunosuppressive therapy completed less than three months before inclusion in the study;
• Female subjects during pregnancy or breastfeeding;
• Acute coronary syndrome or stroke suffered less than one year before inclusion into the study;
• Tuberculosis, chronic systemic infections;
• Aggravated allergy anamnesis (anamnesis of anaphylactic shock, Quinque edema, polymorphic exudative eczema, atopia, serum disease), hypersensitivity or allergic reactions to immunobiological drugs, known allergic reactions to the components of the drug, aggravation of allergic diseases on the day of inclusion in the study;
• The presence of neoplasms in the anamnesis (codes C00-D09);
• Donated blood or plasma (450 ml or more) less than 2 months before inclusion in the study;
• Splenectomy in anamnesis;
• Neutropenia (decrease in absolute number of neutrophils less than 1000/mm3), agraneulocytosis, significant haemorrhage, severe anaemia (hemoglobin less than 80 g/l), immunodeficiency in anamnesis for 6 months before inclusion in the study;
• Subjects with an active form of disease caused by human immunodeficiency virus, syphilis, hepatitis B and C;
• Anorexia, protein deficiency of any origin;
• Chronic autoimmune diseases or systemic collagenoses in anamnesis
• Extensive tattoos at the injection site (deltoid region) that do not allow for an assessment of the local response to IMP/placebo administration;
• Alcoholism and drug addiction in anamnesis;
• Participation of the subject in any other interventional clinical trial;
• Any other condition of the subject which, in the opinion of the researcher's medical practitioner, may prevent completion of the investigation according to the protocol;
• Staff of research centers and other staff directly involved in the study and their families.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Primary Group; Gam-COVID-Vac combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)	Biological: Gam-COVID-Vac; vaccine for intramuscular injection
Placebo Comparator: Control Group; placebo, 0,5ml/dose+0,5 ml/dose immunization in days 1 and 21	Other: Placebo; placebo comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose	Demonstrate the superiority of Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection compared to placebo, based on the percentage of trial subjects with coronavirus disease 2019 (COVID-19) developed within 6 months after the second dose of the study drug/placebo, as confirmed with the method of polymerase chain reaction (PCR)	through the whole study, an average of 180 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the severity of the clinical course of COVID-19	Assess the efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus compared to placebo, based on the severity of the clinical course of COVID-19	through the whole study, an average of 180 days
Changing of antibody levels against the SARS-CoV-2 glycoprotein S	Assess the immunogenicity of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection compared to placebo, based on the geometric mean titer of SARS-CoV-2 glycoprotein-specific antibodies	day before injecting the first dose of the study drug/placebo and 42±2 and 180±14 days after the first dose
Incidence of adverse events in trial subjects	Incidence of adverse events in trial subjects compared to placebo	through the whole study, an average of 180 days
Severity of adverse events in trial subjects	Severity of adverse events in trial subjects compared to placebo	through the whole study, an average of 180 days

Collaborators and Investigators

• Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
• Collaborators: Russian Direct Investment Fund; CRO: iPharma
• Investigators: Study Chair: Roman Plotnikov, CRO: iPharma

Study record dates

Study Major Dates

• Study Start (Actual): September 28, 2020
• Primary Completion (Anticipated): March 28, 2021
• Study Completion (Anticipated): April 10, 2021

Study Registration Dates

• First Submitted: September 24, 2020
• First Submitted That Met QC Criteria: September 24, 2020
• First Posted (Actual): September 25, 2020

Study Record Updates

• Last Update Posted (Actual): December 2, 2020
• Last Update Submitted That Met QC Criteria: December 1, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: SARS-CoV-2; COVID-19; vector vaccine; adenoviral vector
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: 04-Gam-COVID-Vac-2020-RB

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No